The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Anti-CLL1 CAR-T cell therapy in pediatric R/R AML
Rayne H Rouce, MD, Baylor College of Medicine, Houston, TX & Texas Children’s Hospital, Houston, TX, provides a summary of the Phase I trial (ChiCTR1900027684) of an anti-CLL1 2nd generation chimeric antigen receptor (CAR) T-cell therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (AML). Whilst CAR T-cell therapy has been successful in treating B-cell malignancies, CAR T-cell-based leukemia treatment in AML are limited due to disease heterogeneity. In a cohort of 11 patients, 10 completely responded to treatment, demonstrating efficacy and safety. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
